Articles

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial

University Hospital, Heidelberg; Germany
Asklepios Hospital Hamburg Altona; Germany
Klinikum Chemnitz; Germany
University Hospital, Heidelberg; Germany
University Hospital, Heidelberg; Germany;National Center for Tumor Diseases, Heidelberg; Germany
German Cancer Research Center, Heidelberg; Germany
German Cancer Research Center, Heidelberg; Germany
Charité Universitätsmedizin, Berlin; Germany
University Hospital, Köln; Germany
University Hospital, Heidelberg; Germany
University Hospital, Heidelberg; Germany
University Hospital, Heidelberg; Germany
University Hospital, Heidelberg; Germany
University Hospital, Heidelberg; Germany
University Hospital, Heidelberg; Germany
University Medical Center, Mainz; Germany
University Hospital, Bonn; Germany
Helios Hospital, Berlin Buch; Germany
Kath. Krankenhaus, Hagen; Germany
Asklepios Hospital St. Georg, Hamburg; Germany
University Hospital, Tübingen; Germany
University Hospital Essen, Germany
University Hospital, Heidelberg; Germany;National Center for Tumor Diseases, Heidelberg; Germany
Vol. 100 No. 7 (2015): July, 2015 https://doi.org/10.3324/haematol.2015.124347